Necrobiosis Lipoidica Study
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
About Necrobiosis Lipoidica
Necrobiosis Lipoidica is a chronic skin condition that develops on the lower leg but can also occur in other areas such as the face, scalp, forearm, and trunk. Necrobiosis Lipoidica usually presents initially as red papules that enlarge to form patches or plaques with a yellow center. It is more common in women and in diabetic patients. No approved therapies exist and the current treatment approaches are based on empirical evidence. Potent topical steroids are often prescribed as the first line of therapy.
About the Study
Necrobiosis Lipoidica often leads to ulcerations which prove difficult to treat and can also lead to more severe complications such as deep tissue infections and death of bone tissue that can threaten the life of the limb and lead to amputation. The purpose of this study is to evaluate the safety and efficacy of PCS499 in treating ulcerations and increasing the patient’s quality of life.
Am I Eligible?
- Must be 18-80 years of age
- Biopsy confirmed diagnosis; or done at screening visit if not within last 5 years
- Must have at least 1 (2cm2 ) ulcer on leg
- Max of 6 ulcers
What Should I Expect?
- 9 study visits
- 3 phone call check-ins
- Will receive an oral tablet with tapered dosing (PCS499)
Other Information (if applicable)
- Will be compensated for every completed visit
If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.